MedTrace Logo

Safety and Tolerability of ACU-4429

NCT00703183 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-06-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of a new investigational drug (ACU-4429) in healthy human volunteers.

Conditions

  • Healthy

Interventions

DRUG

ACU-4429

administered as a single dose, orally

DRUG

matching placebo

administered as a single dose, orally

Sponsors & Collaborators

  • Kubota Vision Inc.

    lead INDUSTRY

Principal Investigators

  • William W Lewis, M.D. · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703183 on ClinicalTrials.gov